These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 29691590)
41. Metabolic and epigenetic reprogramming in the arsenic-induced cancer stem cells. Li L; Bi Z; Wadgaonkar P; Lu Y; Zhang Q; Fu Y; Thakur C; Wang L; Chen F Semin Cancer Biol; 2019 Aug; 57():10-18. PubMed ID: 31009762 [TBL] [Abstract][Full Text] [Related]
42. Multifaceted Roles of DNA Methylation in Neoplastic Transformation, from Tumor Suppressors to EMT and Metastasis. Casalino L; Verde P Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32806509 [TBL] [Abstract][Full Text] [Related]
43. Tumoral stem cell reprogramming as a driver of cancer: Theory, biological models, implications in cancer therapy. Vicente-Dueñas C; Hauer J; Ruiz-Roca L; Ingenhag D; Rodríguez-Meira A; Auer F; Borkhardt A; Sánchez-García I Semin Cancer Biol; 2015 Jun; 32():3-9. PubMed ID: 24530939 [TBL] [Abstract][Full Text] [Related]
44. Roles of enhancer RNAs in sex hormone-dependent cancers. Zhang L; Ye X; Luo J; Chen J; Zheng W; Wu M J Cancer Res Clin Oncol; 2022 Feb; 148(2):293-307. PubMed ID: 35064362 [TBL] [Abstract][Full Text] [Related]
46. Cell Reprogramming in Tumorigenesis and Its Therapeutic Implications for Breast Cancer. Chu PY; Hou MF; Lai JC; Chen LF; Lin CS Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013830 [TBL] [Abstract][Full Text] [Related]
48. Tumoral reprogramming: Plasticity takes a walk on the wild side. Campos-Sánchez E; Cobaleda C Biochim Biophys Acta; 2015 Apr; 1849(4):436-47. PubMed ID: 25038581 [TBL] [Abstract][Full Text] [Related]
49. Cellular reprogramming and hepatocellular carcinoma development. Zheng YW; Nie YZ; Taniguchi H World J Gastroenterol; 2013 Dec; 19(47):8850-60. PubMed ID: 24379607 [TBL] [Abstract][Full Text] [Related]
50. Tumor-Derived Exosomes and Their Role in Cancer Progression. Whiteside TL Adv Clin Chem; 2016; 74():103-41. PubMed ID: 27117662 [TBL] [Abstract][Full Text] [Related]
51. Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets. Bacabac M; Xu W Cancer Metastasis Rev; 2023 Jun; 42(2):471-480. PubMed ID: 37059907 [TBL] [Abstract][Full Text] [Related]
52. [Cancer Cells as Dynamic System - Molecular and Phenotypic Changes During Tumor Formation, Progression and Dissemination]. Sommerová L; Ondroušková E; Hrstka R Klin Onkol; 2016; 29 Suppl 4(Suppl 4):6-11. PubMed ID: 27846714 [TBL] [Abstract][Full Text] [Related]
53. An Integrated View of Virus-Triggered Cellular Plasticity Using Boolean Networks. Alfaro-García JP; Granados-Alzate MC; Vicente-Manzanares M; Gallego-Gómez JC Cells; 2021 Oct; 10(11):. PubMed ID: 34831086 [TBL] [Abstract][Full Text] [Related]
54. DNA Damage Signaling-Induced Cancer Cell Reprogramming as a Driver of Tumor Relapse. Filipponi D; Emelyanov A; Muller J; Molina C; Nichols J; Bulavin DV Mol Cell; 2019 May; 74(4):651-663.e8. PubMed ID: 30954402 [TBL] [Abstract][Full Text] [Related]
55. Identification of activated enhancers and linked transcription factors in breast, prostate, and kidney tumors by tracing enhancer networks using epigenetic traits. Rhie SK; Guo Y; Tak YG; Yao L; Shen H; Coetzee GA; Laird PW; Farnham PJ Epigenetics Chromatin; 2016; 9():50. PubMed ID: 27833659 [TBL] [Abstract][Full Text] [Related]
56. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Bhat GR; Sethi I; Sadida HQ; Rah B; Mir R; Algehainy N; Albalawi IA; Masoodi T; Subbaraj GK; Jamal F; Singh M; Kumar R; Macha MA; Uddin S; Akil ASA; Haris M; Bhat AA Cancer Metastasis Rev; 2024 Mar; 43(1):197-228. PubMed ID: 38329598 [TBL] [Abstract][Full Text] [Related]
57. Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer. Ravindran Menon D; Hammerlindl H; Torrano J; Schaider H; Fujita M Theranostics; 2020; 10(14):6261-6277. PubMed ID: 32483452 [TBL] [Abstract][Full Text] [Related]